Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4

Journal of Clinical Gastroenterology

Volumn 46, Issue 10, 2012, Pages 871-879

  Khattab, Mahmoud Aboelneen ^a   Eslam, Mohammed ^a   Aly, Mayada M ^a   Shatat, Mohammed ^a   Hussen, Azaa ^a   Moussa, Yossef I ^a   Elsaghir, Ghada ^a   Abdalhalim, Hesham ^a   Aly, Ahmed ^a   Gaber, Salwa ^a   Harrison, Stephen A ^b  

^a MINIA UNIVERSITY   (Egypt)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

adiopcytokines; chronic hepatitis C genotype 4; insulin resistance

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FAS ANTIGEN; HIGH MOLECULAR WEIGHT ADIPONECTIN; INTERLEUKIN 6; LEPTIN; PEPTIDES AND PROTEINS; PROTEIN M30; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; GENE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPOKINES; ADIPONECTIN; ADULT; AGE FACTORS; ANTIGENS, CD95; APOPTOSIS; BODY MASS INDEX; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; LEPTIN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ADIPONECTIN; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84867746778     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318256b68a     Document Type: Article

References (38)

1. Ghany MG, Strader DB, Thomas DL, et al; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
2. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int. 2009;29(suppl 1):89-99.
3. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut. 2011;60:1139-1151.
4. Okuda M, Li K, BeardMR, et al.Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366-375.
5. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39:273-278.
6. Pianko S, Patella S, Ostapowicz G, et al. Fas mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat. 2001;8:406-413.
7. Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol. 2007;13:4865-4872.
8. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957-969.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
10. Wedemeyer I, Bechmann LP, Odenthal M, et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol. 2009;50:140-149.
11. Huang H, Park PH, McMullen MR, et al. Mechanisms for the anti-inflammatory effects of adiponectin in macrophages. J Gastroenterol Hepatol. 2008;23(suppl 1):S50-S53.
12. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate activated protein kinase. Hepatology. 2008;47:677-685.
13. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762-769.
14. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005;100:1509-1515.
15. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-641.
16. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970-1977.
17. Vettor R, Milan G, Rossato M, et al. Review article: adipocytokines' and insulin resistance. Aliment Pharmacol Ther. 2005;22(suppl 2):3-10.
18. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279-1287.
19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
20. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004;40:1078-1087.
21. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
22. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474.
23. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut. 2005;54:117-121.
24. Walsh MJ, Vanags DM, Clouston AD, et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39:1230-1238.
25. Sun Y, Liu S, Ferguson S, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem. 2002;277:23301-23307.
26. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007;46:66-73.
27. O'Brien RM, Lucas PC, Forest CD, et al. Identification of a sequence in the PEPCK gene that mediates a negative effect of insulin on transcription. Science. 1990;249:533-537.
28. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab. 2003;285:E685-E692.
29. Baranova A, Jarrar MH, Stepanova M, et al. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion. 2011;83:32-40.
30. Jonsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol. 2005;43:929-936.
31. Tilg H. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. Curr Pharm Des. 2010;16:1893-1895.
32. Xu AM, Wang Y, Keshaw H, et al. The fat derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
33. Derbala M, Rizk N, Al-Kaabi S, et al. Adiponectin changes in HCV-genotype 4: relation to liver histology and response to treatment. J Viral Hepat. 2009;16:689-696.
34. Tacke F, Wü stefeld T, Horn R, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005;42: 666-673.
35. Sohara N, Takagi H, Kakizaki I, et al. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int. 2005;25: 28-32.
36. Galle PR, Krammer PH. CD95-induced apoptosis in human liver disease. Semin Liver Dis. 1998;18:141-151.
37. Sun Y, Chen X. Effect of adiponectin on apoptosis: proapoptosis or antiapoptosis? Biofactors. 2010;36:179-186.
38. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.